The fully linked HTML version of this article has now been published.
Development ePress online publication date 26 Jan 2005
doi: 10.1242/dev.01648
Research article
Thyroid hormone T3 acting through the thyroid hormone
receptor is necessary for implementation of erythropoiesis in the neonatal spleen environment in the mouse
Cristina Angelin-Duclos,
Chantal Domenget,
Andrea Kolbus,
Hartmut Beug,
Pierre Jurdic,
and
Jacques Samarut*
* Author for correspondence (e-mail: jacques.samarut{at}ens-lyon.fr)
Thyroid hormones (THs) mediate many physiological and developmental functions in vertebrates. All these functions are mediated by binding of the active form of the TH T3 to the specific nuclear receptors TR
and TR
, which are transcription factors. Using mutant mice lacking TRs or deficient for TH production, we show that T3 influences neonatal erythropoiesis through TR
. The effect of T3 and TR
is restricted to this developmental window and is specific for the spleen but not for other erythropoietic organs. We show that T3 via TR
affects late steps of erythrocytic development, promoting the proliferation of late basophilic erythroblasts. In vitro, this effect is exerted directly on erythrocytic cells. In vivo, the action of T3 is also intrinsic to spleen erythrocytic progenitors, as shown by grafting experiments of splenocytes derived from wild-type and TR
knockout (TR
0/0) mice into wild-type and TR
0/0 irradiated recipients. Our results indicate that defective spleen erythropoiesis in hypothyroid and TR
0/0 mice results from impaired recognition of the spleen environment by the mutant erythrocytic progenitors. The data presented support a model in which T3 signaling through TR
is essential for the implementation of the transient spleen erythropoiesis at birth.
This article has been cited by other articles:

|
 |

|
 |
 
T. S. Kendrick, C. J. Payne, M. R. Epis, J. R. Schneider, P. J. Leedman, S. P. Klinken, and E. Ingley
Erythroid defects in TR{alpha}-/- mice
Blood,
March 15, 2008;
111(6):
3245 - 3248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Quignodon, S. Vincent, H. Winter, J. Samarut, and F. Flamant
A Point Mutation in the Activation Function 2 Domain of Thyroid Hormone Receptor {alpha}1 Expressed after CRE-Mediated Recombination Partially Recapitulates Hypothyroidism
Mol. Endocrinol.,
October 1, 2007;
21(10):
2350 - 2360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Flamant, K. Gauthier, and J. Samarut
Thyroid Hormones Signaling Is Getting More Complex: STORMs Are Coming
Mol. Endocrinol.,
February 1, 2007;
21(2):
321 - 333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Flamant, J. D. Baxter, D. Forrest, S. Refetoff, H. Samuels, T. S. Scanlan, B. Vennstrom, and J. Samarut
International Union of Pharmacology. LIX. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Thyroid Hormone Receptors
Pharmacol. Rev.,
December 1, 2006;
58(4):
705 - 711.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Liu, R. Pop, C. Sadegh, C. Brugnara, V. H. Haase, and M. Socolovsky
Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo
Blood,
July 1, 2006;
108(1):
123 - 133.
[Abstract]
[Full Text]
[PDF]
|
 |
|
© The Company of Biologists Ltd 2005